

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

**Mereo BioPharma Group plc**

---

(Name of Issuer)

**Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares**

---

(Title of Class of Securities)

**589492107**

---

(CUSIP Number)

**06/30/2025**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

---

SCHEDULE 13G

CUSIP No. 589492107

Names of Reporting Persons

1 Frazier Life Sciences Public Fund, L.P.

Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	32,430,690.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	32,430,690.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	32,430,690.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	4.1 %
12	Type of Reporting Person (See Instructions)
	PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 32,430,690 Ordinary Shares of the Issuer, represented by 6,486,138 American Depositary Shares held directly by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

**CUSIP No.** 589492107

1	Names of Reporting Persons
	FHMLSP, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	32,430,690.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	32,430,690.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person

32,430,690.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.1 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 32,430,690 Ordinary Shares of the Issuer, represented by 6,486,138 American Depositary Shares held directly by Frazier Life Sciences Public Fund, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

### SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons

1

FHMLSP, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of Shares

Shared Voting Power

6

Beneficially Owned by

32,430,690.00

Each

Sole Dispositive Power

7

Reporting Person

0.00

With:

Shared Dispositive

8

Power

32,430,690.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

32,430,690.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

4.1 %

Type of Reporting Person (See Instructions)

12

OO

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 32,430,690 Ordinary Shares of the Issuer, represented by 6,486,138 American Depositary Shares held directly by Frazier Life Sciences Public Fund, L.P. The

percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

CUSIP No. 589492107

1	Names of Reporting Persons
	Frazier Life Sciences Public Overage Fund, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	8,941,155.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8
	Power
	8,941,155.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	8,941,155.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	1.1 %
12	Type of Reporting Person (See Instructions)
	PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 8,941,155 Ordinary Shares of the Issuer, represented by 1,788,231 American Depositary Shares held directly by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

CUSIP No. 589492107

1	Names of Reporting Persons
	FHMLSP Overage, L.P.
2	Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5  
0.00

Number of Shares Beneficially Owned by Each Reporting Person

6 Shared Voting Power

8,941,155.00

Sole Dispositive Power

7  
0.00

With: Shared Dispositive

8 Power

8,941,155.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9  
8,941,155.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11  
1.1 %

Type of Reporting Person (See Instructions)

12  
PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 8,941,155 Ordinary Shares of the Issuer, represented by 1,788,231 American Depositary Shares held directly by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons

1  
FHMLSP Overage, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2  
 (a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5  
0.00

Number of Shares Beneficially Owned by Each Reporting Person

6 Shared Voting Power

8,941,155.00

7 Sole Dispositive Power

Person  
With: 0.00  
Shared Dispositive  
8 Power  
8,941,155.00  
Aggregate Amount Beneficially Owned by Each Reporting Person  
9  
8,941,155.00  
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  
10  
  
Percent of class represented by amount in row (9)  
11  
1.1 %  
Type of Reporting Person (See Instructions)  
12  
OO

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 8,941,155 Ordinary Shares of the Issuer, represented by 1,788,231 American Depositary Shares held directly by Frazier Life Sciences Public Overage Fund, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons  
1  
Frazier Life Sciences X, L.P.  
Check the appropriate box if a member of a Group (see instructions)  
2  
 (a)  
 (b)  
3  
Sec Use Only  
Citizenship or Place of Organization  
4  
DELAWARE  
Sole Voting Power  
5  
0.00  
Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With: 6  
Shared Voting Power  
1,763,230.00  
Sole Dispositive Power  
7  
0.00  
Shared Dispositive  
8  
Power  
1,763,230.00  
Aggregate Amount Beneficially Owned by Each Reporting Person  
9  
1,763,230.00  
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  
10  
  
Percent of class represented by amount in row (9)  
11

0.2 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depositary Shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

### SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons

1

FHMLS X, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

Shared Voting Power

6

1,763,230.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

1,763,230.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

1,763,230.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depositary Shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

### SCHEDULE 13G

## Names of Reporting Persons

1

FHMLS X, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

 (a) (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person  
With:

Shared Voting Power

6

1,763,230.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

1,763,230.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

1,763,230.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

OO

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depositary Shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

## Names of Reporting Persons

1

Frazier Life Sciences XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

 (a) (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power  
 0.00  
 Shared Voting Power  
 6  
 4,065,485.00  
 Sole Dispositive Power  
 7  
 0.00  
 Shared Dispositive Power  
 8  
 4,065,485.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

4,065,485.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 0.5 %

12 Type of Reporting Person (See Instructions)

PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 4,065,485 Ordinary Shares of the Issuer, represented by 813,097 American Depositary Shares held directly by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 589492107

1 Names of Reporting Persons

FHMLS XI, L.P.

Check the appropriate box if a member of a Group (see instructions)

2  (a)  
 (b)

3 Sec Use Only

4 Citizenship or Place of Organization

DELAWARE

Sole Voting Power  
 5  
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 6 Shared Voting Power  
 4,065,485.00  
 Sole Dispositive Power  
 7

0.00  
 Shared Dispositive Power  
 8  
 4,065,485.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

4,065,485.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.5 %

Type of Reporting Person (See Instructions)

12

PN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 4,065,485 Ordinary Shares of the Issuer, represented by 813,097 American Depositary Shares held directly by Frazier Life Sciences XI, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

### SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons

1

FHMLS XI, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of Shares

Shared Voting Power

6

4,065,485.00

Beneficially Owned by Each

Sole Dispositive Power

7

0.00

Reporting Person

Shared Dispositive

With:

8

Power

4,065,485.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

4,065,485.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.5 %

Type of Reporting Person (See Instructions)

12

OO

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 4,065,485 Ordinary Shares of the Issuer, represented by 813,097 American Depositary Shares held directly by Frazier Life Sciences XI, L.P. The percentage listed

in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

CUSIP No. 589492107

1	Names of Reporting Persons
	James N. Topper
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	UNITED STATES
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	1,763,230.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8
	Power
	1,763,230.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,763,230.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	0.2 %
12	Type of Reporting Person (See Instructions)
	IN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depositary Shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

CUSIP No. 589492107

1	Names of Reporting Persons
	Patrick J. Heron
2	Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only  
Citizenship or Place of Organization

4 UNITED STATES

Sole Voting Power

5

0.00

Number of Shares Beneficially Owned by Each Reporting Person

Shared Voting Power

6

1,763,230.00

Sole Dispositive Power

7

0.00

With: Shared Dispositive

8

Power

1,763,230.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

1,763,230.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.2 %

Type of Reporting Person (See Instructions)

12

IN

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depositary Shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 795,001,444 Ordinary Shares outstanding on May 12, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

## SCHEDULE 13G

CUSIP No. 589492107

Names of Reporting Persons

1

Albert Cha

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person

5

0.00

Shared Voting Power

6

0.00

7 Sole Dispositive Power

Person With: 0.00  
 Shared Dispositive Power  
 8 0.00  
 Aggregate Amount Beneficially Owned by Each Reporting Person  
 9 0.00  
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  
 10   
 Percent of class represented by amount in row (9)  
 11 0.0 %  
 Type of Reporting Person (See Instructions)  
 12 IN

## SCHEDULE 13G

**CUSIP No.** 589492107

Names of Reporting Persons  
 1 James Brush  
 Check the appropriate box if a member of a Group (see instructions)  
 2  (a)  
 (b)  
 3 Sec Use Only  
 Citizenship or Place of Organization  
 4 UNITED STATES  
 Sole Voting Power  
 5 0.00  
 Number of Shares Beneficially Owned by Each Reporting Person With:  
 6 Shared Voting Power 0.00  
 7 Sole Dispositive Power 0.00  
 8 Shared Dispositive Power 0.00  
 Aggregate Amount Beneficially Owned by Each Reporting Person  
 9 0.00  
 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)  
 10   
 Percent of class represented by amount in row (9)  
 11 0.0 %  
 Type of Reporting Person (See Instructions)  
 12 IN

## SCHEDULE 13G

CUSIP No. 589492107

Names of Reporting Persons

1

Daniel Estes

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of  
Shares

Shared Voting Power

6

0.00

Beneficially  
Owned by

Sole Dispositive Power

7

0.00

Each  
Reporting  
Person

Shared Dispositive

With:

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.0 %

Type of Reporting Person (See Instructions)

12

IN

## SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Mereo BioPharma Group plc

Address of issuer's principal executive offices:

(b)

4th Floor, One Cavendish Place, London, X0, W1G 0QF.

Item 2.

(a)

Name of person filing:

The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper

("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")

Address or principal business office or, if none, residence:

- (b) The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304  
Citizenship:

- (c) The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.

Title of class of securities:

- (d) Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares  
CUSIP No.:

- (e) 589492107

Item 3. If this statement is filed pursuant to Â§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  
(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  
(c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  
(d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  
(e)  An investment adviser in accordance with Â§ 240.13d-1(b)(1)(ii)(E);  
(f)  An employee benefit plan or endowment fund in accordance with Â§ 240.13d-1(b)(1)(ii)(F);  
(g)  A parent holding company or control person in accordance with Â§ 240.13d-1(b)(1)(ii)(G);  
(h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  
(i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);  
 A non-U.S. institution in accordance with Â§ 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in  
(j) accordance with Â§ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:  
(k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 32,430,690 Ordinary Shares of the Issuer, represented by 6,486,138 American Depository Shares. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 8,941,155 Ordinary Shares of the Issuer, represented by 1,788,231 American Depository Shares. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS X directly holds 1,763,230 Ordinary Shares of the Issuer, represented by 352,646 American Depository Shares. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 4,065,485 Ordinary Shares of the Issuer, represented by 813,097 American Depository Shares. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.

Percent of class:

- (b) The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP  
Name/Title: of FHMLSP, L.P., GP of Frazier Life Sciences  
Public Fund, L.P.

Date: 08/14/2025

FHMLSP, L.P.

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP  
Name/Title: of FHMLSP, L.P.

Date: 08/14/2025

FHMLSP, L.L.C.

Signature: /s/ Steve R. Bailey

Name/Title: By Steve R. Bailey, CFO of FHMLSP, L.L.C.

Date: 08/14/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLSP Overage,  
Name/Title: L.L.C., GP of FHMLSP Overage, L.P., GP of  
Frazier Life Sciences Public Overage Fund, L.P.  
Date: 08/14/2025

FHMLSP Overage, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLSP Overage,  
Name/Title: L.L.C., GP of FHMLSP Overage, L.P.  
Date: 08/14/2025

FHMLSP Overage, L.L.C.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLSP Overage,  
Name/Title: L.L.C.  
Date: 08/14/2025

Frazier Life Sciences X, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLS X, L.L.C.,  
Name/Title: GP of FHMLS X, L.P., GP of Frazier Life  
Sciences X, L.P.  
Date: 08/14/2025

FHMLS X, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLS X, L.L.C.,  
Name/Title: GP of FHMLS X, L.P.  
Date: 08/14/2025

FHMLS X, L.L.C.

Signature: /s/ Steve R. Bailey  
Name/Title: By Steve R. Bailey, CFO of FHMLS X, L.L.C.  
Date: 08/14/2025

Frazier Life Sciences XI, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,  
Name/Title: GP of FHMLS XI, L.P., GP of Frazier Life  
Sciences XI, L.P.  
Date: 08/14/2025

FHMLS XI, L.P.

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.,  
Name/Title: GP of FHMLS XI, L.P.  
Date: 08/14/2025

FHMLS XI, L.L.C.

Signature: /s/ Steve R. Bailey  
Name/Title: By Steve R. Bailey, CFO of FHMLS XI, L.L.C.  
Date: 08/14/2025

James N. Topper

Signature: /s/ Steve R. Bailey  
By Steve R. Bailey, Attorney-in-Fact for James N.  
Name/Title: Topper, pursuant to a Power of Attorney, a copy  
of which was filed with the SEC on July 31, 2017

Patrick J. Heron

Date: 08/14/2025

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017

Date: 08/14/2025

Albert Cha

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

Date: 08/14/2025

James Brush

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

Date: 08/14/2025

Daniel Estes

Signature: /s/ Steve R. Bailey

By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022

Date: 08/14/2025

#### **Exhibit Information**

Exhibit 99.1 Joint Filing Agreement, dated as of April 4, 2025, incorporated by reference into this Statement.